Veradermics Sets Nov. 9 Call to Unveil 12-Month Phase 3 '302' Hair Loss Data
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics will host an investor call and webcast Monday, November 9 at 8:00 am ET to review topline 12-month results from Part B of the Phase 3 '302' trial of VDPHL01, its extended-release oral minoxidil, in over 500 men with mild-to-moderate pattern hair loss. The call is the data event itself — the results are not in this release, so direction is unknown until the numbers land. This follows the October 19 disclosure that Phase 3 Study '304' hit both co-primary endpoints with high statistical significance in 536 men, which is the bar the '302' readout will be measured against. VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both men and women if approved, and the company cites a market projected near $30 billion by 2028. Note the stock sits near its 52-week high after a wave of insider selling in August, including a $80.4 million block at $107.25, so positioning is crowded into this print.
At the time of this announcement, MANE was trading at $139.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $32.00 to $146.58. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.